141 related articles for article (PubMed ID: 12438230)
1. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
Wang Y; Zhao R; Chattopadhyay S; Goldman ID
Cancer Res; 2002 Nov; 62(22):6434-7. PubMed ID: 12438230
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
Zhao R; Babani S; Gao F; Liu L; Goldman ID
Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
[TBL] [Abstract][Full Text] [Related]
4. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
5. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier.
Zhao R; Chattopadhyay S; Hanscom M; Goldman ID
Clin Cancer Res; 2004 Dec; 10(24):8735-42. PubMed ID: 15623659
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Adjei AA
Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
[TBL] [Abstract][Full Text] [Related]
8. [Pemetrexed: from preclinic to clinic].
Lansiaux A; Lokiec F
Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
[TBL] [Abstract][Full Text] [Related]
9. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
10. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
Zhao R; Gao F; Babani S; Goldman ID
Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
[TBL] [Abstract][Full Text] [Related]
12. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
[TBL] [Abstract][Full Text] [Related]
13. Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells.
Chattopadhyay S; Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Dec; 10(23):7986-93. PubMed ID: 15585634
[TBL] [Abstract][Full Text] [Related]
14. The molecular identity and characterization of a Proton-coupled Folate Transporter--PCFT; biological ramifications and impact on the activity of pemetrexed.
Zhao R; Goldman ID
Cancer Metastasis Rev; 2007 Mar; 26(1):129-39. PubMed ID: 17340171
[TBL] [Abstract][Full Text] [Related]
15. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism.
McGuire JJ; Haile WH; Yeh CC
Cancer Res; 2006 Apr; 66(7):3836-44. PubMed ID: 16585211
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
17. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
Zhao R; Hanscom M; Chattopadhyay S; Goldman ID
Cancer Res; 2004 May; 64(9):3313-9. PubMed ID: 15126375
[TBL] [Abstract][Full Text] [Related]
18. Biochemical pharmacology of pemetrexed.
Calvert AH
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):13-7. PubMed ID: 15655931
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
Wang Y; Zhao R; Goldman ID
Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
[TBL] [Abstract][Full Text] [Related]
20. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]